Neoadjuvant chemotherapy using platinum- and taxane-based regimens for bulky stage Ib2 to IIb non-squamous cell carcinoma of the uterine cervix

• DOI: 10.1007/s00280-012-2052-2
• Publication Date: 2012-12-22T02:07:36Z
• Authors: Tadahiro Shoji; Eriko Takatori; Tatsunori Saito; Hideo Omi; Masahiro Kagabu; Fumiharu Miura; Satoshi Takeuchi; Toru Sugiyama
• Keywords: Carboplatin; Leukopenia; Regimen; Taxane

There are no reports on the use of neoadjuvant chemotherapy (NAC) in non-squamous cell cervical carcinoma. We examined effectiveness and safety paclitaxel/carboplatin (TC) docetaxel/carboplatin (DC).Stage Ib2 to IIb disease was present 23 patients scheduled for radical hysterectomy. administered 1-3 courses either TC or DC regimen. Anti-tumor effects were found superior by Response Evaluation Criteria Solid Tumors. Safety assessed with National Cancer Institute Common Terminology Adverse Events.Median age 50 years (range 32-63 years), stage 6 cases (26.1%) 17 (73.9%). Complete response achieved 5 (21.7%), partial 13 (56.5%), stable (21.7%); rate 78.3%, surgery completion 78.3%. Leukopenia neutropenia ≥grade 3 seen 12 (52.2%) 21 (91.3%) cases, respectively, grade febrile 2 (8.7%) anemia thrombocytopenia 3. Median progression-free survival 26 months (95% Cl, 13.5-38.5 months); median overall 35 20.9-49.1 months).NAC carcinoma showed potent anti-tumor manageable adverse events.